研究单位：[1]Hoffmann-La Roche[2]Beijing Hospital,Beijing City,China,100006[3]Beijing Cancer Hospital,Beijing,China,100142[4]Jilin Cancer Hospital,Changchun,China,132013[5]Hu Nan Provincial Cancer Hospital,Changsha,China,410006[6]Third Xiangya Hospital Centrel South University,Changsha,China,410013[7]Sichuan Cancer Hospital,Chengdu City,China,610041[8]Southwest Hospital , Third Military Medical University,Chongqing,China,400038[9]Fujian Cancer Hospital,Fuzhou,China,350014[10]Sun Yet-sen University Cancer Center,Guangzhou City,China,510663[11]The First Affiliated Hospital of Guangzhou Medical University,Guangzhou,China,510120[12]Shulan (Hangzhou) Hospital,Hangzhou City,China,310003[13]Harbin Medical University Cancer Hospital,Harbin,China,150081[14]Anhui Province Cancer Hospital,Hefei City,China,230031[15]Shandong Cancer Hospital,Jinan,China,250117[16]Guangxi Cancer Hospital of Guangxi Medical University,Nanning,China,530021[17]Fudan University Shanghai Cancer Center[18]Medical Oncology,Shanghai City,China,201315[19]Tianjin Cancer Hospital,Tianjin,China,300060[20]Tumor Center,Union Hospital, Tongji Medical College, Huazhong University of Science and Technology,Wuhan,China,430023[21]Hubei Cancer Hospital,Wuhan,China,430079[22]First Affiliated Hospital of Medical College of Xi'an Jiaotong University,Xi''an,China,710061[23]Henan Cancer Hospital,Zhengzhou,China,450008
研究目的：
This is a multicenter, double-blind, placebo-controlled, randomized, phase II study to investigate the efficacy and safety of Atezolizumab with or without Tiragolumab as consolidation therapy in participants with limited stage small cell lung cancer who have not progressed during/after chemoradiotherapy.
